Tokai Pharmaceuticals has raised $23m in a Series D3 financing to support the ongoing clinical development of galeterone (TOK-001), a treatment for castration-resistant prostate cancer.

TOK-001, the company’s lead drug candidate, has completed an initial proof-of-concept Phase I clinical trial, and additional funding will advance galeterone into Phase II clinical development.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Galeterone’s novel triple mechanism of action against the growth and survival of prostate cancer cells differentiates it from other for castration-resistant prostate cancer therapies, Williams said.

The Phase I proof-of-concept clinical trial, part of the Androgen Receptor Modulation Optimized for Response (ARMOR) clinical development programme, enrolled 49 patients to evaluate dose escalating levels of galeterone and safety and reduction in prostate-specific antigen levels from baseline levels.

The financing round was led by current investors, Novartis Venture Fund and Apple Tree Partners.

See Also:

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.